H.C. Wainwright Upbeat on OncoSec Medical Following Updated Phase 2 Data


OncoSec Medical (NASDAQ:ONCS) just hit clinical trial results out of the park in the melanoma arena, with a Phase 2 combination trial that has H.C. Wainwright analyst Ram Selvaraju looking ahead to better clinical outcomes in patients not responsive to solely anti-PD-1 therapy.

Story Continues